Visus in the limelight

As an active clinical-stage pharmaceutical company on the leading-edge of ophthalmic innovations, we’re bound to be making headlines. Check back often for the very latest updates, announcements, and breakthroughs that are propelling us forward.

Discover our pipeline today.

With officies in Seattle and Orange County, Visus is home to our lead clinical candidate, BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia.

CORPORATE PROFILE

Visus Therapeutics is a clinical-stage company in pursuit of developing the the world's first presbyopia-correcting eye drop with the potential to last at least eight hours.
‍
With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.

Media contact: media@visustx.com

Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies to improve vision for people around the world. Our pipeline of early-stage ophthalmic product candidates includes applications in ocular surface disease, glaucoma, and age-related macular degeneration.

COMPANY PRESENTATIONS

Visus Therapeutics to Present at 2023 JMP Securities Life Science Conference

Visus CEO Ben Bergo presents Topline BRIO-I data at the JMP Securities Conference on Monday, May 15th. To register and view the live webcast, please click here.

News Article

March 9, 2021

Visus Therapeutics Gathers $36 Million to Develop Presbyopia Drug